An observational study in Pediatric ALL and Radiotherapy Side Effect, sponsored by Umeå University. Completed. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2016-12-15.
Sponsored by Umeå University · Observational
The purpose of the study is to evaluate the effect of changes in the care environment in pediatric radiotherapy. The definitions of the changes is a part of the study, and is constructed in collaboration with the institute of design at Umeå University. The implementation is however not part of the study, but done as part of Clinical routine.
The study consist of two parts, where the first 1.5 years are a Control phase where the changes are designed and also function as a baseline period. The following 1.5 years are the case period where the Changes that are accepted for Clinical implementation are implemented.
The impact of the changes are evaluated using surveys and interviews of both parents and children
The purpose of the study is to evaluate the effect of changes in the care environment in pediatric radiotherapy. The definitions of the changes is a part of the study, and is constructed in collaboration with the institute of design at Umeå University. The implementation is however not part of the study, but done as part of Clinical routine.
The study consist of two parts, where the first 1.5 years are a Control phase where the changes are designed and also function as a baseline period. The following 1.5 years are the case period where the Changes that are accepted for Clinical implementation are implemented.
The impact of the changes are evaluated using surveys and interviews of both parents and children. Interviews of the personnel regarding their experiences of the study and the changes is performed after the finalization of the case period.
2,121 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 492 are open to participants now.
This study's enrollment of 57 is below the median of 120 across 313 observational studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →Umeå University is the lead sponsor of 271 studies on the registry; 60 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All pediatric patients treated with radiotherapy at the study centres were candidates for the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-
Pediatric patients and their parents who were treated with radiotherapy during baseline period and enrolled in the study. Recruitment to the Control Group took Place during one year.
Pediatric patients and their parents who were treated with radiotherapy during case period and enrolled in the study. Recruitment to the case group took place during one year after introduction of new methods and equipment in the in the clinic..
Parents anxiety during treatment period
VAS-anxiety scoring in connection to therapy
Time frame: 1 day
Childrens anxiety during treatment period
FAS-evaluation
Time frame: 1 day
Parents quality of Life during treatment period
PedsQL survey
Time frame: 1 day
Parents view of the care and care environment
Semi structured interview
Time frame: After treatment period (within 2 months after last treatment)
Childrens reflections regarding the treatment period
Semi structured interview
Time frame: After treatment period (within 2 months after last treatment)
Use of sedative treatment in connection to radiotherapy
The use of sedative treatments were recorded for each fraction
Time frame: up to 2 months
Experiences of the personnel
Interviews
Time frame: After the case period (within 1 year)
No study locations are listed for this record.
Plan to share: No
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Precursor Cell Lymphoblastic Leukemia-Lymphoma →